Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct:63:1-29.
doi: 10.1016/j.freeradbiomed.2013.03.018. Epub 2013 Apr 6.

Mitochondrial diseases of the brain

Affiliations
Review

Mitochondrial diseases of the brain

Rajnish K Chaturvedi et al. Free Radic Biol Med. 2013 Oct.

Abstract

Neurodegenerative disorders are debilitating diseases of the brain, characterized by behavioral, motor and cognitive impairments. Ample evidence underpins mitochondrial dysfunction as a central causal factor in the pathogenesis of neurodegenerative disorders including Parkinson's disease, Huntington's disease, Alzheimer's disease, Amyotrophic lateral sclerosis, Friedreich's ataxia and Charcot-Marie-Tooth disease. In this review, we discuss the role of mitochondrial dysfunction such as bioenergetics defects, mitochondrial DNA mutations, gene mutations, altered mitochondrial dynamics (mitochondrial fusion/fission, morphology, size, transport/trafficking, and movement), impaired transcription and the association of mutated proteins with mitochondria in these diseases. We highlight the therapeutic role of mitochondrial bioenergetic agents in toxin and in cellular and genetic animal models of neurodegenerative disorders. We also discuss clinical trials of bioenergetics agents in neurodegenerative disorders. Lastly, we shed light on PGC-1α, TORC-1, AMP kinase, Nrf2-ARE, and Sirtuins as novel therapeutic targets for neurodegenerative disorders.

Keywords: 1-methyl-4-phenyl-1,2,3,6-tetrahydrodropyridine; 1-methyl-4-phenylpyridinium; 6-OHDA; 6-hydroxydopamine; AD; ALS; AMP-activated protein kinase; AMPK; Alzheimer’s disease; Amyotrophic Lateral Sclerosis; Amyotrophic lateral sclerosis; BAT; CK; Charcot-Marie-Tooth disease and Friedreich’s ataxia; Co-Q10; CoQ10; Creatine; Drp1; Free radicals; HD; Huntington’s Disease; Huntington’s disease; KGDH; MFN; MMP; MPP+; MPTP; Mitochondrial dysfunction; Neurodegenerative diseases; PCr; PD; PGC-1α; PPARs; Parkinson’s disease; ROS; Sirtuins; TAR DNA; TCA; TORC; Tfam; Transduceres of Creb-related binding protein; UCP-1; alpha-ketoglutarate dehydrogenase; binding protein TDP-43; brown adipose tissue; coenzymeQ10; creatine kinase; dynamin-related protein 1; mitochondrial DNA; mitochondrial membrane potential; mitochondrial transcription factor A; mitofusin; mtDNA; peroxisome proliferator-activated receptors; phosphocreatine; proliferator-activated receptor-gamma coactivator-1alpha; reactive oxygen species; tricarboxylic acid cycle; uncoupling proteins.

PubMed Disclaimer

Publication types

MeSH terms